Not applicableNo Longer AvailableNCT00063791What this trial is testingAssess Two Different Strategies of Combining Dexamethasone and VELCADEWho this might be right forMultiple Myeloma Millennium Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07523555What this trial is testingAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesWho this might be right forRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more Beijing Biotech 96
Early research (Phase 1)Looking for participantsNCT06153251What this trial is testingAssess BMS-986453 in Participants With Relapsed and/or Refractory Multiple MyelomaWho this might be right forRelapsed and/or Refractory Multiple Myeloma Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Early research (Phase 1)Active Not RecruitingNCT06425991What this trial is testingA Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Janssen Research & Development, LLC 108
Testing effectiveness (Phase 2)Study completedNCT03860038What this trial is testingTJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma in RelapseRefractory Multiple Myeloma TJ Biopharma Co., Ltd. 113
Not applicableApproved For MarketingNCT01632826What this trial is testingPomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Celgene
Large-scale testing (Phase 3)Active Not RecruitingNCT05028348What this trial is testingCombination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple MyelomaWho this might be right forMultiple Myeloma European Myeloma Network B.V. 117
Testing effectiveness (Phase 2)UnknownNCT04287855What this trial is testingMulticenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma in RelapseMultiple Myeloma, Refractory Poitiers University Hospital 82
Testing effectiveness (Phase 2)Ended earlyNCT00441168What this trial is testingVelcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple MyelomaWho this might be right forMultiple Myeloma Janssen-Cilag International NV 30
Large-scale testing (Phase 3)Study completedNCT01239797What this trial is testingPhase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaWho this might be right forLymphomaMultiple Myeloma Bristol-Myers Squibb 646
Early research (Phase 1)Ended earlyNCT01999335What this trial is testingOprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Amgen 33
Early research (Phase 1)Study completedNCT02955550What this trial is testingA Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)Who this might be right forMultiple Myeloma Celularity Incorporated 15
Early research (Phase 1)Looking for participantsNCT07003568What this trial is testingDual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary InfiltrationWho this might be right forRelapsed or Refractory Multiple Myeloma (RRMM) Beijing GoBroad Hospital 18
Not applicableStudy completedNCT02075996What this trial is testingNon-interventional Study With Pomalidomide (Imnovid®)Who this might be right forMultiple Myeloma iOMEDICO AG 151
Post-approval studies (Phase 4)WithdrawnNCT05183139What this trial is testingIn-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Takeda
Testing effectiveness (Phase 2)Ended earlyNCT01177683What this trial is testingBendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple MyelomaWho this might be right forMultiple Myeloma Sherif Farag, MB, BS 32
Testing effectiveness (Phase 2)Study completedNCT00618345What this trial is testingEverolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Mayo Clinic 35
Not applicableStudy completedNCT06163040What this trial is testingEvaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in TaiwanWho this might be right forRelapsed or Refractory Multiple Myeloma Bristol-Myers Squibb 7
Testing effectiveness (Phase 2)Ended earlyNCT05117008What this trial is testingMaintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple MyelomaWho this might be right forRefractory Multiple MyelomaRelapse Multiple Myeloma Medical College of Wisconsin 1
Early research (Phase 1)Not Yet RecruitingNCT07735546What this trial is testingUB-VV500 With Rapamycin in Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma in RelapseMultiple Myeloma (MM) Umoja Biopharma 100